Novo Nordisk Sues Eli Lilly Over Deceptive Weight-Loss Drug Ads
LLY sits 83% above its 52-week low of $623.78.
Summary
Novo Nordisk filed a deceptive advertising lawsuit against Eli Lilly in New Jersey district court, alleging Lilly's ads mislead consumers by comparing Zepbound's 50-pound average weight loss to Wegovy's 33 pounds using outdated data. Novo claims a higher-dose Wegovy approved in March shows comparable 47-pound loss, making the comparison unfair. The suit escalates the battle for the $80 billion weight-loss market, where Lilly gained share by touting superior efficacy. Novo seeks an immediate court order to pull the ads and financial damages, including profits from the campaign. This follows a cease-and-desist letter in April that Lilly ignored. The outcome could impact Lilly's marketing strategy and market share if ads are blocked. Novo Nordisk also says mismatched diabetes drug ads triggered the lawsuit against Lilly.
At the time of this announcement, LLY was trading at $1,140.88 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.